San Francisco, United States
Calmsie is a startup that aims to revolutionize the way children's mental health is addressed. Their solution, Mission Amygdala, is a personalized, multi-modal experience designed to cater to the individual needs and preferences of children, ultimately driving engagement and efficacy. By utilizing data-based digital biomarkers, Calmsie enhances the diagnostic process and accurately predicts treatment outcomes. The mission unfolds within a mobile app, where children embark on a personalized space adventure, helping characters navigate and overcome emotional challenges. Mission Amygdala can function as a standalone treatment or complement traditional therapy, streamlining care and improving patient outcomes, particularly targeting mild to moderate depression and anxiety in children aged 8-12.
Calmsie, with headquarters in the United States and a branch in Poland, presents an innovative approach to addressing mental health issues in children, an area that is often overlooked. The startup was founded in 2020 and focuses on the education and healthcare industries. Notably, they have yet to disclose their last investment and associated investors. For potential venture capital investors seeking to delve into the realm of children's mental health, Calmsie presents an intriguing opportunity. For investment inquiries, Marcin Waryszak can be contacted at [email protected].
